Search Results for "CT P6 Celltrion"
By Kurt R. Karst – Earlier this week, Celltrion Healthcare Co., Ltd. and Celltrion, Inc. (collectively “Celltrion”) filed a Complaint for Declaratory Judgment in the U.S. District...
Celltrion Inc. (KOSDAQ:068270) gained W4,100 to W47,400 on Wednesday on rumors in South Korean media outlets that multiple companies were engaged in talks to acquire the Korean biosimilar play. Roche...
As you no doubt know, Celltrion, the big Korean CMO, is up for sale. It's biggest investor Chairman Seo Jung Jin wants to part with his $1.3 B stake in the company and is actively seeking buyers. Fier...
Speculation is swirling around Celltrion again, this time regarding a possible acquisition of the South Korean biosimilars company by a major foreign pharma firm, despite continuing controversy surrou...
Signaling a probe is imminent, local media reported that state prosecutors have banned Celltrion’s CEO from leaving Korea over alleged stock manipulation.
Celltrion reveals little about the progress of Chairman Seo Jung-jin’s share sell-off as the company’s clinical development moves forward on a Rituxan biosimilar.
Beyond its main focus of biosimilars, Celltrion is pursuing an influenza therapy that would be its first original product.
Celltrion expects Korea’s National Health Insurance to cover Remsima and to start sales in the third quarter.
Matching PubMed Articles